ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Coronavirus

Fujifilm to restart Avigan COVID-19 trials in Japan

Drug has already been approved in India and Indonesia for emergency use

Flu-fighting drug Avigan may see a second life in Japan as a COVID-19 treatment with a new trial set to begin in April.   © Reuters

TOKYO -- Japan's Fujifilm Holdings will restart a clinical trial for its flu-fighting drug Avigan to treat Japanese COVID-19 patients as early as April, Nikkei has learned, giving new life to the medication that had been seen as a potential game changer in the early stages of the pandemic.

Avigan, which has already been approved in India and Indonesia for emergency use to treat COVID-19 patients, could not win the green light in Japan last year after a health ministry expert board postponed a decision in December. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more